Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI-0001 in pediatric relapsed or refractory CD19-positive acute lymphoblastic leukemia
2022-001101-52Phase 2Active
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Aug 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI-0001 in acute lymphoblastic leukemia (ALL), sponsored by Fundació Sant Joan de Déu. Primary endpoint: Complete response rate with MRD negativity by day +100. Started Aug 2022; status: active.
02
Drugs
ARI-0001
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2022-001101-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001101-52.